Eight Oncology Drug Launches Expected In 2022 – Solid Tumors
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are eight new oncology products to treat solid tumors that could make their market debuts next year.
Inovio Pharmaceuticals, Inc. plans to file for regulatory approval of its DNA vaccine candidate VGX-3100 for the treatment of cervical dysplasia caused by HPV 18 and 16 before the end of 2021.
However, the company will need additional data and longer follow-up to confirm its benefit after topline results from the Phase...